Quality Indicators for Human Milk Use in Very Low Birthweight Infants: Are We Measuring What We Should be Measuring?

Harold R. Bigger, MD, Rush University Medical Center
Louis J. Fogg, PhD, Rush University Medical Center
Aloka Patel, MD, Rush University Medical Center
Tricia Johnson, PhD, Rush University Medical Center
Janet L. Engstrom, PhD, RN, CNM, WHNP-BC, and Frontier Nursing University, Rush University Medical Center
Paula P. Meier, PhD., RN, Rush University Medical Center

Abstract

Objective—The objective of this study was to compare the currently used human milk (HM) quality indicators that measure whether very low birthweight (VLBW; <1500 g birthweight) infants “ever” received HM and whether they were still receiving HM at discharge from the neonatal intensive care unit (NICU) to the actual amount and timing of HM received.

Study Design—This study used data from a large NIH-funded cohort study and calculated whether VLBW infants ever received HM (HM-Ever) and of these infants, the percentage who were still receiving HM at NICU discharge (HM-DC). Then, the HM-DC indicator (exclusive, partial and none) was compared with the amount and timing of HM feedings received by these same infants.

Results—Of the 291 VLBW infants who met inclusion criteria, 285 received some HM (HM-Ever = 98%). At NICU discharge (HM-DC), 24.2%, 15.1% and 60.7% were receiving exclusive, partial and no HM, respectively. Of the 60.7% infants with no HM-DC, some had received higher amounts of HM during the NICU hospitalization than infants categorized as exclusive and partial for HM-DC. Of the infants with no HM-DC, 76.8% and 59.7% had received exclusive HM during the Days 1–14 and Days 1–28 exposure periods, respectively.
Conclusion—The average daily dose (HM-DD; in mL/kg/d) and cumulative percentage (HM-PCT; as % of cumulative enteral intake) of HM feedings were sufficient to significantly reduce the risk of multiple morbidities, including late onset sepsis, necrotizing enterocolitis, neurocognitive delay and rehospitalization, in the majority of the VLBW infants who were discharged with no HM-DC. Quality indicators that focus on the amount and timing of HM feedings in the NICU should be added to the HM-Ever and HM-DC measures.

Keywords

VLBW infants; NICU; human milk; quality indicators; prematurity-related morbidities

Human milk (HM; milk from the infant’s own mother) feedings during the neonatal intensive care unit (NICU) hospitalization reduce the risk of prematurity-related morbidities in a dose-response manner for very low birth weight (VLBW; <1500 g birth weight; includes extremely low birth weight; ELBW; <1000 g birth weight) infants. (1) These morbidities, which include late onset sepsis, necrotizing enterocolitis, chronic lung disease and retinopathy of prematurity, prolong the NICU hospitalization, increase health care costs and predispose the infant to long-term health and educational problems. (1–8) A dose-response relationship between the amount of HM feedings received during the NICU hospitalization and a reduction in the risks of neurodevelopmental delay and rehospitalization at 18 and 30 months of age, corrected for prematurity, has also been demonstrated for this population. (9, 10) These clinical outcomes have led individual NICUs and care networks to establish quality improvement programs focused on increasing the use of HM during the NICU hospitalization for VLBW infants. (11, 12)

A first step in this quality improvement process is the identification of measurable HM quality indicators that reflect the latest evidence. For HM feedings in the NICU, recent research has consistently linked the amount and timing of HM feedings with a reduction in the risk of morbidities during and after the NICU hospitalization in VLBW infants. (1) However, the current quality indicators for HM feeding in the NICU do not measure the amount or timing of HM feeding. Instead, these indicators measure two simple characteristics of HM feeding: 1) whether the infant ever received any HM milk during the NICU stay, regardless of the amount or timing of the milk; and 2) whether the infant was receiving exclusive, partial, and no HM feedings on the day of NICU discharge. (11–13) Although calculations based on the use of the current HM quality indicators are simple and easy to perform, the indicators are imprecise, and do not reflect the amount and timing of actual human milk feedings that impact health outcomes during and after the infant’s NICU hospitalization.

The purpose of this study was to compare the currently used HM quality indicators to the actual amount and timing of HM received by VLBW infants during the NICU hospitalization to determine whether the quality indicators provide adequate information about HM feeding in the NICU. Specifically, we described the amounts of HM received during critical periods of the NICU hospitalization (Days 1–14 and Days 1–28 post-birth) as well as throughout the NICU stay, and then compared these data to the currently used HM
quality indicators of ever receiving HM and still receiving HM at the time of NICU discharge.

Methods

Sample

This study is part of a larger ongoing prospective cohort study examining health outcomes and cost of HM feedings for VLBW infants conducted in a 57-bed tertiary NICU in Chicago. (14) For the larger study, all eligible infants and their mothers were offered enrollment, and data were collected from the time of the infant’s NICU admission through NICU discharge. Eligibility criteria for the larger study included: birth weight <1500 g; gestational age ≤35 weeks; absence of severe congenital anomalies; negative maternal drug screen at birth; admitted to the study NICU within 24 hours of birth; infant under legal custody of birth mother; and feedings initiated before day 14 of life. Maternal initiation of lactation was not an inclusion criterion for enrollment. In the case of multiple births, one infant from each set of multiples was selected randomly for inclusion in the study. For the research reported here, additional exclusions included infants who did not survive, were transferred to another institution prior to NICU discharge, or whose length of stay was over 180 days. This study was approved by the Rush University Institutional Review Board, and signed informed consent was obtained from parents or guardians of all enrolled subjects.

Measures

All measures were extracted from the database for the larger study and included maternal and infant demographic and clinical data, as well as the following daily measures for each infant: weight, intake (mLs) of clear intravenous fluids, parenteral nutrition fluids, HM, and formula.

Human Milk Quality Indicators—The two current HM quality indicators are 1) whether an infant had ever received HM (HM-Ever), and 2) whether the infant was receiving HM at the time of NICU discharge (HM-DC). These variables were calculated for each infant in the following manner. If any HM feedings had been documented in the database for the infant, regardless of the amount or timing, the HM-Ever was classified as “yes”. If only formula feedings were documented, the HM-Ever was classified as “no”. HM-DC was calculated by examining the infant’s type of feedings on the last full day of hospitalization prior to NICU discharge (12A-12A), and classifying infants into three mutually-exclusive categories: exclusive HM (only fortified or unfortified HM, and no formula); partial HM (some HM and some formula); and no HM (only formula; no HM). During the study period no human donor milk was used so the infants received only their own mother’s milk. This milk was fortified with proprietary powdered bovine additives following a standardized procedure.

Amount of HM Feedings—The amount of HM feedings received by infants was measured both as a weight adjusted daily dose (mL/kg/d) and as a percentage of total enteral feedings that consisted of HM. These measures were selected because several studies have demonstrated either a reduction in the risk or the incidence of a specific morbidity as a...
function of receiving either a threshold dose (2, 6, 9, 10, 15, 16) or percentage of HM feedings. (3–5, 8)

**Daily dose of human milk (HM-DD):** The HM-DD was calculated for each infant for each day of the NICU hospitalization as follows. The total number of mLs of HM (fortified and unfortified) received by the infant during a 24 hour period from 12AM to 12AM was summed, and then divided by the infant's measured weight for that day, and expressed as mL/kg/d.

**Daily percentage of enteral feedings consisting of HM (HM-PCT):** The HM-PCT was calculated to determine the relative amounts of human milk and formula received by each infant for each day of the NICU hospitalization as follows. For a 24 hour period from 12AM to 12AM, the total number of mLs of HM and formula were calculated. Then, the mLs of HM was divided by the sum of the mLs of HM and formula, and then multiplied by 100 (\(\frac{\text{mLs HM}}{\text{mLs HM} + \text{mLs formula}} \times 100\)).

**Timing of HM Feedings—** The timing of HM feedings was measured by creating three post-birth exposure period variables that have been linked to a reduction in the risk and/or incidence of morbidities in VLBW infants as a function of the amount of HM received: the first 14 days post-birth (Days 1–14); (3–5, 8) the first 28 days post-birth (Days 1–28; includes the first 14–days post-birth); (2, 6, 16) and the total NICU hospitalization. (9, 10, 16) For each of these exposure periods, the average daily dose of HM (Average HM-DD) and the cumulative percentage of HM (Cumulative HM-PCT) were calculated.

**Average HM-DD:** The Average HM-DD was calculated for each infant for the exposure period of interest by summing the individual HM-DDs for each infant for the days within the exposure period and then dividing this sum by the number of days in the exposure period. Average HM-DD was calculated for Days 1–14, Days 1–28 and the total NICU hospitalization.

**Cumulative HM-PCT:** The Cumulative HM-PCT was calculated as the percentage of enteral intake that consisted of HM over the specific exposure period, rather than being calculated as a daily measure and then summed. Specifically, for the exposure period of interest, the mLs of HM and formula for the days within the exposure period were summed. Then, the sum of the mLs of HM was divided by the sum of mLs of HM plus the sum of the mLs of formula, and this figure was multiplied by 100 (\(\frac{\text{sum of mLs HM}}{\text{sum of mLs HM} + \text{sum of mLs formula}} \times 100\)). Cumulative HM-PCT was calculated for Days 1–14, Days 1–28 and the total NICU hospitalization.

**Data Analyses**

Data were analyzed using Excel (Redmond, WA) and SPSS 15.0 (Chicago, IL, USA). Descriptive statistics were used to summarize the demographic characteristics of infants and the HM feeding variables and for all dose and exposure period measures.
Results

A total of 324 VLBW infants were enrolled into the larger cohort study between February 2008 and August 2012. Of these 324 subjects, 291 infants met the inclusion criteria for this analysis. Of the 33 ineligible subjects, 26 infants were transferred to a different institution prior to NICU discharge, so HM-DC could not be verified. An additional three infants did not survive, and four had a length of stay that exceeded 180 days.

Quality indicator #1: Ever received HM during the NICU hospitalization (HM-Ever)

Of the 291 infants in the study, 285 received some HM during the NICU hospitalization, corresponding to a value of 98% for the HM-Ever quality indicator. The characteristics of the infants who ever and never received HM are reported in Table 1. For the 285 infants who received HM during the NICU hospitalization, the average HM-DD and cumulative HM-PCT are summarized in Table 2. For the 285 infants, the actual fed volume of HM during the NICU hospitalization ranged from 3 - 28,229 mLs. For the Days 1–14 and 1–28 exposure periods, 63.2% and 44.8%, respectively, of these infants received exclusive HM feedings. The median cumulative HM-PCT for Days 1–14 and Days 1–28 were 100% and 98%, respectively.

Quality indicator #2: Human Milk Feeding at NICU Discharge (HM-DC)

Of the 285 infants who ever received HM, the HM-DC status was: 69 (24.2%) of the infants were receiving exclusive HM feedings, 43 (15.1%) were receiving partial HM feedings, and 173 (60.7%) were receiving no HM. Table 2 summarizes the medians of average HM-DDs and medians of cumulative HM-PCTs for each category of HM feeding at discharge (exclusive, partial or no HM), during the critical periods (days 1–14 and 1–28) and for the entire NICU hospitalization.

Table 2 reveals that of the 173 infants categorized as receiving no HM at NICU discharge, many of the infants had received significant amounts of HM, especially during the early post-birth exposure periods of Days 1–14 and Days 1–28. Of these infants receiving only formula at the time of NICU discharge, 44 (25.4%) of the infants received an average HM-DD ≥50 mL/kg/d for the entire NICU hospitalization, and 29.6% of NICU days consisted of exclusive HM feedings. Additionally, for the no HM at NICU discharge infants, 76.8% and 59.7% received exclusive HM during Days 1–14 and Days 1–28, respectively. The median cumulative HM-PCTs for Days 1–14 and Days 1–28 were 100% and 68.3%, respectively.

Figures 1a & b shows graphically that some infants categorized as no HM at NICU discharge had actually received higher amounts of HM and higher cumulative proportions of HM than did infants categorized as partial or exclusive HM feedings at NICU discharge during the first 28 days of life.

Discussion

The findings from this study illustrate the limitations in using HM-Ever and HM-DC as the only quality indicators for evaluating the use of HM for VLBW infants in the NICU. Of the 291 infants enrolled in our study, 285 (98%) were categorized as receiving some HM, using
the HM-Ever quality indicator, and 112 (39.3%) of these infants were categorized as still receiving some HM at the time of NICU discharge using the HM-DC measure. Thus, the HM-DC quality measure was not met for 173 (60.7%) infants, all of whom were grouped into a single “no HM” category, regardless of the actual amount and timing of HM feedings that were received during the NICU hospitalization. It is easy to conclude that the NICU did not achieve quality HM use for 60.7% of the infants in this study.

However, a closer look at the data for the 285 infants who ever received HM reveals that irrespective of the HM-DC status, the amount of HM they received was sufficient to reduce the risk of many morbidities during and after the NICU hospitalization. (1–10, 16) For example, the median of average HM-DDs for the NICU hospitalization was 58.3 mL/kg/d, an amount of HM that exceeds the ≥50 mL/kg/d threshold dose that has been linked to a reduction in the risk of several morbidities during the NICU hospitalization. (2, 6, 16) Furthermore, even smaller amounts of HM received during the NICU hospitalization have been shown to impact morbidities in the post-NICU period in a dose-response manner. (2–5, 8–10) In one large multi-site study of 1034 ELBW infants, each 10 mL/kg/day of HM during the NICU hospitalization translated into points gained in neurodevelopmental and behavioral scores and in a reduction in the risk of rehospitalization at 18 and 30 months of age, corrected for prematurity. (9, 10) Thus, even the infants in our study who received <50 mL/kg/d of HM during the NICU hospitalization would be at lower risk for these post-NICU morbidities than infants who never received HM, regardless of the HM-DC quality measure.

Our findings about the extremely high amounts of HM received during Days 1–14 and Days 1–28 for this cohort further exemplify the limitations in the currently used HM-DC quality indicators. Several outcome studies have addressed the impact of HM feedings in the reduction in the risk, incidence and severity, and cost of NEC and late onset sepsis in VLBW infants, and these studies form the scientific basis for prioritizing the use of HM in this population. (1–5, 5–8, 15, 16) However, these prematurity-specific morbidities are not affected by whether or not the infant is still receiving HM at the time of NICU discharge; they are mediated by the amount of HM received in Days 1–14 and Days 1–28. For example, Johnson et al demonstrated a threefold increase in the risk of NEC in VLBW infants as a function of receiving any formula (e.g., <100% cumulative HM-PCT) during Days 1–14 (8), and Sisk et al. (3) reported a six-fold reduction in the risk of NEC when VLBW infants received a cumulative HM-PCT ≥50% during this same Days 1–14 exposure period. Similarly, Patel et al. (2) demonstrated a dose-response relationship between average HM-DD and the risk of late onset sepsis and its associated costs in VLBW infants, such that each additional 10 mL/kg/d of HM during Days 1–28 reduced the risk of sepsis by 19%. In our study, the 173 infants who received no HM at NICU discharge would have been at significantly less risk for the development of NEC and late onset sepsis due to the high amounts of HM received in the early postbirth period. For this group of infants the median of average HM-DDs and the median cumulative HM-PCTs for Days 1–14 were 14.6 mL/kg/d and 100%, respectively for Days 1–28 they were 26.6 mL/kg/d and 68.3%, respectively. These amounts of early HM feedings were sufficient to reduce the risk, incidence/severity and costs associated with NEC and late onset sepsis, even though the infants were considered “failures” with respect to the HM-DC quality indicator.
The importance of adding quality indicators that measure the amount of HM received by VLBW infants during Days 1–14 and 1–28 is underscored by a solid body of mechanistic research that details “why” high amounts of HM are essential to the reduction in risk of morbidities in VLBW infants. It is well-established that high-dose (and in some instances, 100%) early HM feedings, especially colostrum, promote the growth, maturation and protection of the gut epithelial border. (17–27) HM feedings have been shown to stimulate healthy gut microflora, reduce intestinal permeability, and interfere with the translocation of bacteria from the gut lumen to the mucosa, and appear to be the most critical as VLBW infants transition from intrauterine (e.g., swallowing amniotic fluid) to extrauterine nutrition in the early post-birth period. (1, 17–23, 26–33) There is also evidence that commercial formulas may have a separate detrimental impact on these processes during these early post-birth exposure periods, via up-regulation of inflammatory processes, GIT epithelial cell toxicity and other mechanisms. (1, 8, 18, 19, 23, 2, 27) Although the combination of the clinical outcomes and mechanistic research about the impact of HM in the early post-birth period for VLBW infants is compelling, as yet it has not been integrated into HM quality improvement measures. (1)

It is likely that the currently used NICU quality indicators were adapted from national goals for the initiation and duration of breastfeeding that were first proposed in 1984 and continue today. (34–38) Although intended primarily for healthy populations of mothers and infants, their use with VLBW infants was appropriate when NICU lactation care was prioritized primarily to sustain lactation in mothers who wanted to feed at the breast after discharge. However, in the last decade, research has linked specific amounts and timing of HM use with a reduction in the risk of morbidities in VLBW infants. (1) With the evolution of this evidence, our findings reveal that these current HM quality indicators do not adequately measure the amount and timing of HM feedings received by VLBW infants. Additional HM quality indicators should include the average DD-HM and the cumulative PCT-HM for three critical exposure periods: Days 1–14, Days 1–28 and the NICU hospitalization.

The strengths of our study include the large sample size, prospectively collected feeding data and the variability in the actual amounts of HM received by the sample of infants. Our study findings are limited in that the actual volumes of HM were clustered into either very high or very low categories and were not normally distributed. This was especially true for HM-PCT during days 1–14, when the median value was 100% for the 285 infants. Additionally, our study focused on currently used quality indicators for VLBW infants in the NICU rather than the Joint Commission Perinatal Core Measure for exclusive breastfeeding during the maternity hospitalization, as the latter initiative focuses primarily on healthy term infants. (39–40)

We conclude that average HM-DD and cumulative HM-PCT during Days 1–14, 1–28 and the entire NICU hospitalization should be added to the existing HM-Ever and HM-DC quality indicators for measuring the use of HM in VLBW infants. With the widespread use of electronic medical records, these and other quality indicators based on the amount and timing of HM feedings (e.g., percentage of NICU fed-days equal to exclusive HM) are simple to perform and easily linked to clinical outcome measures, cost of care and other quality improvement initiatives.
Acknowledgments

This research was supported by a grant from the National Institutes of Health (NIH Grant # NR010009).

References

1. Meier PP, Engstrom IL, Patel AL, Jegier BJ, Bruns N. Improving the use of human milk during and after the NICU stay. Clin Perinatol. 2010; 37(1):217–45. [PubMed: 20363457]
2. Patel AL, Johnson TJ, Engstrom JL, Fogg LF, Jegier BJ, Bigger HR, Meier PP. Impact of early human milk on sepsis and health care costs in very low birthweight infants. J Perinatol. 2013; 33(7): 514–9. [PubMed: 23370606]
3. Sisk PM, Lovelady CA, Dillard RG, Gruber KJ, O'Shea TM. Early human milk feeding is associated with a lower risk of necrotizing enterocolitis in very low birth weight infants. J Perinatol. 2007; 27:428–33. [PubMed: 17443195]
4. Sisk PM, Lovelady CA, Gruber KJ, Dillard RG, O'Shea TM. Human milk consumption and full enteral feeding among infants who weigh ≤250 grams. Pediatrics. 2008; 121(6):e1528–1533. [PubMed: 18519456]
5. Meinzen-Derr J, Poindexter B, Wraze L, Morrow AL, Stoll B, Donovan EF. Role of human milk in extremely low birth weight infants' risk of necrotizing enterocolitis or death. J Perinatol. 2009 Jan; 29(1):57–62. [PubMed: 18716628]
6. Furman L, Taylor G, Minich N, Hack M. The effect of maternal milk on neonatal morbidity of very low-birth-weight infants. Arch Pediatr Adolesc Med. 2003 Jan; 157(1):66–71. [PubMed: 12517197]
7. Johnson TJ, Patel AL, Jegier B, Engstrom JL, Meier J. The cost of morbidities in very low birth weight infants. Journal of Pediatrics. 2013; 162(2):243–49. [PubMed: 22910099]
8. Johnson, TJ. The cost-effectiveness of human milk feedings as a strategy to reduce the risk of prematurity-specific morbidities in VLBW infants. Proceedings from the 2013 Experimental Biology Meeting; April 20–24, 2013; Boston, MA, p. 61
9. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Wright LL, Langer JC, et al. Beneficial effects of breast milk in the neonatal intensive care unit on the developmental outcome of extremely low birth weight infants at 18 months of age. Pediatrics. 2006; 118(1):e115–23. [PubMed: 16818256]
10. Vohr BR, Poindexter BB, Dusick AM, McKinley LT, Higgins RD, Langer JC, et al. Persistent beneficial effects of breast milk ingested in the neonatal intensive care unit on extremely low birth weight infants at 30 months of age. Pediatrics. 2007 Oct; 120(4):e953–9. [PubMed: 17908750]
11. Kuzma-O'Reilly B, Duenas ML, Greecher C, Kimberlin L, Mujse D, Miller D, et al. Evaluation, development, and implementation of potentially better practices in neonatal intensive care nutrition. Pediatrics. 2003 Apr; 111(4 Pt 2):e461–70. [PubMed: 12671166]
12. Vermont-Oxford Network. Vermont-Oxford Network Database: Manual of Operations. 2013. Report No.: Release April, 2013
13. Davanzo R, Ronfani L, Brovedani P, Demarini S. Breast feeding very-low-birthweight infants at discharge: A multicentre study using WHO definitions. Paediatr Perinat Epidemiol. 2009 Nov; 23(6):591–6. [PubMed: 19840296]
14. Meier PP. Health benefits and cost of human milk for very low birthweight infants. 2007 Oct.;1. R01-NR010009-01.
15. Schanler RJ, Lau C, Hurst NM, Smith EOB. Randomized trial of donor human milk versus preterm formula as substitutes for mothers' own milk in the feeding of extremely premature infants. Pediatrics 2005. Aug 1; 2005 116(2):400–6.
16. Schanler RJ, Shulman RJ, Lau C. Feeding strategies for premature infants: Beneficial outcomes of feeding fortified human milk versus preterm formula. Pediatrics. 1999 Jun.103:1150–7. [PubMed: 10353922]
17. Walker A. Breast milk as the gold standard for protective nutrients. J Pediatr. 2010; 156:S3–7. [PubMed: 20105662]
18. Sangild PT. Gut responses to enteral nutrition in preterm infants and animals. Exp Biol Med. 2006 Dec; 231(11):1695–711.
19. Sangild PT, Siggers RH, Schmidt M, Elnif J, Bjornvad CR, Thymann T, et al. Diet- and colonization-dependent intestinal dysfunction predisposes to necrotizing enterocolitis in preterm pigs. Gastroenterology. 2006 May; 130(6):1776–92. [PubMed: 16697741]
20. Mei J, Zhang Y, Wang T, Sangild PT, Xu RJ. Oral ingestion of colostrum alters intestinal transforming growth factor-beta receptor intensity in newborn pigs. Livestock Science. 2006; 105:214–222.
21. Bjornvad CR, Thymann T, Deutz NE, Burrin DG, Jensen SK, Jensen BB, et al. Enteral feeding induces diet-dependent mucosal dysfunction, bacterial proliferation, and necrotizing enterocolitis in preterm pigs on parenteral nutrition. Am J Physiol Gastrointest Liver Physiol. 2008 Nov; 295(5):G1092–103. [PubMed: 18818317]
22. Siggers RH, Siggers J, Thymann T, Boye M, Sangild PT. Nutritional modulation of the gut microbiota and immune system in preterm neonates susceptible to necrotizing enterocolitis. J Nutr Biochem. 2011 Jun; 22(6):511–21. [PubMed: 21193301]
23. Thymann T, Burrin DG, Tappenden KA, Bjornvad CR, Jensen SK, Sangild PT. Formulafeeding reduces lactose digestive capacity in neonatal pigs. Br J Nutr. 2006 Jun; 95(6):1075–81. [PubMed: 16768828]
24. Underwood MA, Gilbert WM, Sherman MP. Amniotic fluid: Not just fetal urine anymore. J Perinatol. 2005 May; 25(5):341–8. [PubMed: 15861199]
25. Wagner CL, Taylor SN, Johnson D. Host factors in amniotic fluid and breast milk that contribute to gut maturation. Clin Rev Allergy Immunol. 2008 Apr; 34(2):191–204. [PubMed: 18330727]
26. Penn AH. Digested formula but not digested fresh human milk causes death of intestinal cells in vitro: Implications for necrotizing enterocolitis. Pediatr Res. 2012; 72(6):560–7. [PubMed: 23007028]
27. Taylor SN, Basile LA, Ebeling M, Wagner CL. Intestinal permeability in preterm infants by feeding type: Mother's milk versus formula. Breastfeed Med. 2009 Mar; 4(1):11–5. [PubMed: 19196035]
28. Caicedo RA, Schanler RJ, Li N, Neu J. The developing intestinal ecosystem: Implications for the neonate. Pediatr Res. 2005; 58(4):625–8. [PubMed: 16189184]
29. Verhasselt V. Neonatal tolerance under breastfeeding influence. Curr Opin Immunol. 2010 Oct; 22(5):623–30. [PubMed: 20851590]
30. Garofalo R. Cytokines in human milk. J Pediatr. 2010 Feb; 156(2 Suppl):S36–40. [PubMed: 20105664]
31. Shulman RJ, Schanler RJ, Lau C, Heitkemper M, Ou C, Smith EO. Early feeding, antenatal glucocorticoids, and human milk decrease intestinal permeability in preterm infants. Pediatr Res. 1998; 44:519–23. [PubMed: 9773840]
32. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res. 2007 Jan; 61(1):2–8. [PubMed: 17211132]
33. Newburg DS. Innate immunity and human milk. Journal of Human Lactation. 2005
34. U.S. Dept. of Health and Human Services. The surgeon general's call to action to support breastfeeding 2011. Washington, D.C: 2011.
35. American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics. 2012 Mar 01; 129(3):e827–41. [PubMed: 22371471]
36. U.S. Dept. of Health and Human Services. Report of the surgeon general's workshop on breastfeeding & human lactation. 1984.
37. U.S. Dept. of Health and Human Services. Followup Report: The surgeon general's workshop on breastfeeding & human lactation. 1985.
38. Galson S. The 25th anniversary of the surgeon general's workshop on breastfeeding and human lactation: The status of breastfeeding today. Public Health Reports. 2009; 124:356–8. [PubMed: 19445409]
39. The Joint Commission. Specifications manual for joint commission national quality measures (Version 2013A). Oakbrook Terrace, IL: The Joint Commission; 2012. Available from: https://manual.jointcommission.org/releases/TJC2013A/MIF0170.html
40. Feldman-Winter L, Douglass-Bright A, Bartick MC, Matranga J. The new mandate from the joint commission on the perinatal care core measure of exclusive breast milk feeding: Implications for practice and implementation in the united states. J Hum Lact. 2013 Aug; 29(3):291–5. [PubMed: 23599268]
Figure 1.
HM intake over the first 28 days of life. a) dose of HM expressed as average daily dose (mL/kg/day); b) cumulative proportion of HM to enteral feedings. Both panels demonstrate that some infants categorized as no HM at NICU discharge had actually achieved clinically important amounts of HM during the first month of life.
Table 1

Characteristics of the sample (n = 291)

|                          | HM-Ever = Yes n = 285 | HM-Ever = No n = 6 |
|--------------------------|------------------------|--------------------|
| Gestational age (weeks)* | 28.5 ± 2.3             | 30.6 ± 2.3         |
| Birth Weight (grams)*    | 1063.8 ± 252.4         | 1266.2 ± 173.8     |
| Maternal age (years)*    | 27.7 ± 6.5             | 25.2 ± 7.8         |
| Maternal race/ ethnicity** |                       |                    |
| White                    | 53/285 (18.6%)         | 0/6 (0.0%)         |
| Black                    | 147/285 (51.6%)        | 5/6 (83.3%)        |
| Hispanic                 | 80/285 (28.1%)         | 1/6 (16.7%)        |
| Other                    | 5/285 (1.8%)           | 0/6 (0.0%)         |
| Male gender**            | 156/285 (54.7%)        | 2/6 (33.3%)        |
| Multiple gestation**     | 41/285 (14.4%)         | 5/6 (83.3%)        |
| % WIC eligible**         | 186/261 (65.3%)        | 6/6 (100%)         |
| Length of hospitalization (days)* | 71.4 ± 31.0 | 41.7 ± 13.1 |
| PMA at discharge (weeks)* | 38.7 ± 2.9            | 36.6 ± 1.3         |
| Weight at discharge (grams)* | 2616.7 ± 628.8 | 2220.0 ± 452.1    |

Data are presented as either mean ± SD* or frequency (%)**
| HM-DC          | n (%)  | Average HM-DD (mL/kg/d) | Cumulative HM-PCT (%) |
|---------------|--------|-------------------------|-----------------------|
|               |        | median | 25 – 75 percentile | median | 25 – 75 percentile |
| Exclusive HM  |        |        |                   |         |                   |
| Days 1–14     | 69 (24.2%) | 44.9 | 16.4 – 71.6 | 100 | 100 – 100 |
| Days 1–28     | 64 (23.7%)* | 84.2 | 58.9 – 108.8 | 100 | 100 – 100 |
| NICU hospitalization | 69 (24.2%) | 120.6 | 108.7 – 133.4 | 100 | 99.6 – 100 |
| Partial HM    |        |        |                   |         |                   |
| Days 1–14     | 43 (15.1%) | 28.7 | 17.0 – 62.1 | 100 | 72.3 – 100 |
| Days 1–28     | 40 (14.8%)* | 71.1 | 37.5 – 91.3 | 97.8 | 62.3 – 100 |
| NICU hospitalization | 43 (15.1%) | 88.7 | 68.0 – 115.2 | 73.5 | 49.9 – 90.9 |
| No HM         |        |        |                   |         |                   |
| Days 1–14     | 173 (60.7%) | 14.6 | 4.8 – 37.3 | 100 | 58.4 – 100 |
| Days 1–28     | 166 (61.5%)* | 26.6 | 9.2 – 61.4 | 68.3 | 20.4 – 100 |
| NICU hospitalization | 173 (60.7%) | 18.0 | 6.5 – 52.9 | 11.7 | 3.9 – 39.7 |
| Total sample  |        |        |                   |         |                   |
| Days 1–14     | 285 (100%) | 21.9 | 7.2 – 48.9 | 100 | 84.1 – 100 |
| Days 1–28     | 270 (100%)* | 45.7 | 14.4 – 84.7 | 98.0 | 38.6 – 100 |
| NICU hospitalization | 285 (100%) | 58.3 | 13.0 – 109.3 | 45.0 | 9.0 – 95.4 |

*Total reflects infants that were discharged home prior to 28 days post-birth.